Circulating miRNA-375 as a potential novel biomarker for active Kaposi's sarcoma in AIDS patients.


Journal

Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777

Informations de publication

Date de publication:
02 2019
Historique:
received: 20 06 2018
revised: 09 10 2018
accepted: 02 11 2018
pubmed: 15 12 2018
medline: 18 6 2020
entrez: 15 12 2018
Statut: ppublish

Résumé

The aim of this study was to identify circulating microRNAs (miRNAs) that could be used as biomarkers in patients at risk for or affected by AIDS-Kaposi's sarcoma (KS). Screening of 377 miRNAs was performed using low-density arrays in pooled plasma samples of 10 HIV/human herpesvirus 8 (HHV8)-infected asymptomatic and 10 AIDS-KS patients before and after successful combined antiretroviral therapy (cART). MiR-375 was identified as a potential marker of active KS, being the most down-regulated in AIDS-KS patients after cART and the most up-regulated in naïve AIDS-KS patients compared to naïve asymptomatic subjects. Validation on individual plasma samples confirmed that miR-375 levels were higher in AIDS-KS compared to asymptomatic patients, decreased after cART-induced remission in most AIDS-KS patients and increased in patients with active KS. In asymptomatic patients miR-375 was up-regulated after cART in both screening and validation. Statistical analyses revealed an association between miR-375 changes and CD4 cell counts, which could explain the discordant cases and the opposite trend between asymptomatic and AIDS-KS patients. These data suggest that circulating miR-375 might be a good indicator of active AIDS-KS. Moreover, changes in miR-375 levels may have a prognostic value in HIV/HHV8-infected patients undergoing treatment. Further large-scale validation is needed.

Identifiants

pubmed: 30549196
doi: 10.1111/jcmm.14054
pmc: PMC6349189
doi:

Substances chimiques

Biomarkers, Tumor 0
Circulating MicroRNA 0
MIRN375 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1486-1494

Informations de copyright

© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

Références

Int J Cancer. 2014 Sep 1;135(5):1011-8
pubmed: 24166096
Int J Clin Exp Med. 2015 May 15;8(5):7241-50
pubmed: 26221263
Genome Biol. 2009;10(6):R64
pubmed: 19531210
Cancer Lett. 2018 Dec 1;438:126-132
pubmed: 30237038
Blood. 2009 Jun 4;113(23):5938-41
pubmed: 19252139
Infect Agent Cancer. 2016 Feb 03;11:5
pubmed: 26848307
J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13
pubmed: 15167289
Int J Mol Sci. 2016 Apr 27;17(5):
pubmed: 27128908
Cancer Res. 2010 Dec 1;70(23):9798-807
pubmed: 21098710
Tumour Biol. 2015 Jan;36(1):437-46
pubmed: 25266797
Clin Chem. 2010 Nov;56(11):1733-41
pubmed: 20847327
Ann Intern Med. 2015 Oct 6;163(7):507-18
pubmed: 26436616
PLoS Pathog. 2013;9(7):e1003484
pubmed: 23874201
J Cell Mol Med. 2019 Feb;23(2):1486-1494
pubmed: 30549196
J Invest Dermatol. 2014 Feb;134(2):507-517
pubmed: 23962809
Clin Cancer Res. 2018 Dec 1;24(23):5873-5882
pubmed: 30061360
Tumour Biol. 2015 Jun;36(6):4501-7
pubmed: 25618599
Drug Deliv Transl Res. 2014 Feb;4(1):19-30
pubmed: 25786615
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Hum Virol. 1998 Mar-Apr;1(3):207-13
pubmed: 10195244
Int J Oncol. 2005 Sep;27(3):779-85
pubmed: 16077928
World J Gastroenterol. 2017 Jun 7;23(21):3864-3875
pubmed: 28638226
J Clin Microbiol. 2005 Jun;43(6):2866-75
pubmed: 15956410
Pathol Oncol Res. 2014 Jan;20(1):153-9
pubmed: 24027049
Trends Biochem Sci. 2012 Nov;37(11):460-5
pubmed: 22944280

Auteurs

Maria Assunta Piano (MA)

Immunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.

Lisa Gianesello (L)

Immunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.

Angela Grassi (A)

Immunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.

Paola Del Bianco (P)

Clinical Trials and Biostatistics, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.

Adriana Mattiolo (A)

Immunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.

Anna Maria Cattelan (AM)

Infectious and Tropical Diseases, Azienda Ospedaliera and University of Padova, Padova, Italy.

Lolita Sasset (L)

Infectious Diseases, ULSS 18 - Azienda Ospedaliera, Rovigo, Italy.

Paola Zanovello (P)

Immunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.

Maria Luisa Calabrò (ML)

Immunology and Molecular Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH